When Jesse Berry was diagnosed with retinoblastoma, the most common primary intraocular tumor in children, at 18 months of age, he had no idea he'd be doing so for the rest of his life.
"It's always important to remember that we are eye doctors, and these are children with a disease that, if untreated or inappropriately treated, can kill the child," Berry, an eye doctor at St.
Louis Children's Hospital, told the Retina 2023 conference in Hawaii last week, per NBC News.
"The number one goal is to save the child's life, and then their eye, then their vision."
Since retinoblastoma presents with strabismus or leukocoria, an average age of 18 months, it's often treated with enucleation, tumor consolidation, systemic chemoreduction, or external beam radiation.
But there's still a big question: Is there an increased risk of metastatic disease if you give localized, intraarterial chemotherapy vs.
systemic chemotherapy throughout the body? "We still don't have a head-to-head trial to prove that," Berry says.
In the interim, researchers are working on a new treatment that would involve a combination of intraarterial chemotherapy and
A customized collection of grant news from foundations and the federal government from around the Web.
In the world of social enterprises, failure is a cringe-worthy moment nobody wants to talk about. But, social entrepreneurs can benefit from their failures.